Showing results (71-80 of 102) with videos related to
Sort By:
Pageof 11
The Lancet. Gastroenterology & Hepatology|December 5, 2025
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trialMilind Javle, Christos Fountzilas, Chih-Yi Liao, et al.Journal of Clinical Medicine|May 28, 2020
Strategies to Improve Participation of Older Adults in Cancer ResearchJennifer Liu, Eutiquio Gutierrez, Abhay Tiwari, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 23, 2024
Acute cancer-related symptoms and concerns among patients receiving chemotherapy: current state of the scienceKristen S Smith, Aasha I Hoogland, Taylor Welniak, et al.Journal of Geriatric Oncology|March 5, 2021
Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancerYuan Yuan, Jin Sun Lee, Susan E Yost, et al.The Lancet. Oncology|January 24, 2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, studyRichard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2024
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 TrialTeresa Macarulla, Zhenggang Ren, Hong Jae Chon, et al.Psycho-Oncology|October 8, 2025
Acute Change in Perceived Cognitive Performance Across Different Age Groups Following First Chemotherapy Infusion in Female Patients With Breast CancerHui-Ying Yang, Xiaoyin Li, Aasha I Hoogland, et al.Endocrine-Related Cancer|January 22, 2021
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasmsJames C Yao, Jonathan Strosberg, Nicola Fazio, et al.Journal of Hepatology|December 13, 2021
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinomaAnn-Lii Cheng, Shukui Qin, Masafumi Ikeda, et al.The Oncologist|June 1, 2017
Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast CancerYuan Yuan, Nilesh Vora, Can-Lan Sun, et al.Pageof 11